Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and progressive disease, which often leads to premature death …

Pulmonary arterial hypertension (PAH) is an enigmatic and deadly vascular disease with no
known cure. Recent years have seen rapid advances in our understanding of the molecular …

In a remarkably short interval of time, pulmonary artery hypertension (PAH) has evolved from
a disease of unknown pathogenesis devoid of effective therapy to a condition whose cellular …

Pulmonary arterial hypertension (PAH) diagnosis and management have evolved over the
years. Despite advances in management that resulted in an overall improvement of disease …

Pulmonary arterial hypertension (PAH) is a progressive disease. Although great progress
has been made in its diagnosis and treatment in recent years, its mortality rate is still very …

The pathobiology of pulmonary arterial hypertension (PAH) involves a remodeling process
in distal pulmonary arteries, as well as vasoconstriction and in situ thrombosis, leading to an …

Pulmonary arterial hypertension (PAH) is a rare and chronic lung disease characterized by
progressive occlusion of the small pulmonary arteries, which is associated with structural …

In early 2019, the 6th World Symposium on Pulmonary Hypertension (WSPH) released an
updated document highlighting the advances in the last five years. During the quinquennial …

Persistent challenges in managing pulmonary vascular disease progression and poor
outcomes, despite the aggressive use of current drug therapies, highlight the need for …

Pulmonary hypertension may develop as a disease process specific to pulmonary arteries
with no identifiable cause or may occur in relation to other cardiopulmonary and systemic …